Melphalan 5mg Tablet Franchise in Ahmedabad

Anticancer & Chemotherapy Drug Supplier in Mumbai

Melophit 5 Tablet Distributor in Delhi

Oncology Therapy Tablet Franchise Opportunity in Bangalore

Chemotherapy Medicine Stockist in Hyderabad
Melphalan 5mg Export & Manufacturing in Chandigarh

Home/Products /melphalan-5mg-tablet

Melophit 5 Tablet

Composition : Melphalan (5mg) Tablet

Dosage Form : Tablet

Packaging Type : in a Bottle

Packaging : 30 Tablets

Price : ₹1/-

Melophit 5 Tablet contains Melphalan 5mg, a potent alkylating agent widely used in oncology for the treatment of multiple myeloma and selected solid tumors such as ovarian cancer. The higher strength supports flexible dosing strategies in chemotherapy regimens aimed at disease control and remission maintenance.

Melphalan works by cross-linking DNA strands in rapidly dividing malignant cells, inhibiting DNA replication and triggering cell death. This cytotoxic action helps reduce tumor burden and slow disease progression when administered under specialist supervision.

For distributors and healthcare suppliers, Melophit 5 Tablet is a critical oncology therapy product, primarily supplied to cancer hospitals, oncology clinics, and tertiary care institutions. Ongoing requirements for oral chemotherapy agents in long-term cancer management ensure steady and specialized demand.

Adding Melophit 5 Tablet to your oncology and anticancer therapy segment strengthens portfolios across hospital supply chains, specialty pharmacies, export markets, and third-party manufacturing. Its established clinical role, dose flexibility, and importance in cancer treatment protocols make it a valuable product within pharmaceutical oncology distribution.

Read More

About the Product

Melophit 5 Tablet contains Melphalan 5mg, a potent alkylating agent widely used in oncology for the treatment of multiple myeloma and selected solid tumors such as ovarian cancer. The higher strength supports flexible dosing strategies in chemotherapy regimens aimed at disease control and remission maintenance.

Melphalan works by cross-linking DNA strands in rapidly dividing malignant cells, inhibiting DNA replication and triggering cell death. This cytotoxic action helps reduce tumor burden and slow disease progression when administered under specialist supervision.

For distributors and healthcare suppliers, Melophit 5 Tablet is a critical oncology therapy product, primarily supplied to cancer hospitals, oncology clinics, and tertiary care institutions. Ongoing requirements for oral chemotherapy agents in long-term cancer management ensure steady and specialized demand.

Adding Melophit 5 Tablet to your oncology and anticancer therapy segment strengthens portfolios across hospital supply chains, specialty pharmacies, export markets, and third-party manufacturing. Its established clinical role, dose flexibility, and importance in cancer treatment protocols make it a valuable product within pharmaceutical oncology distribution.

Common side effects include nausea, vomiting, diarrhea, loss of appetite, fatigue, and bone marrow suppression resulting in anemia, leukopenia, or thrombocytopenia. Serious side effects may include increased susceptibility to infections, bleeding disorders, or long-term risk of secondary cancers.

Melophit 5 Tablet is indicated for the treatment of multiple myeloma, ovarian carcinoma, and other selected malignancies as prescribed by an oncologist. It may also be used in high-dose or maintenance chemotherapy regimens.

Melophit 5 Tablet must be used only under the supervision of a qualified oncologist. Regular blood tests are essential to monitor bone marrow function. Inform your doctor about any existing infections, unusual bleeding, pregnancy, or breastfeeding before starting treatment.

Store Melophit 5 Tablet in a cool, dry place away from direct sunlight and moisture. Keep out of reach of children. Do not use the tablet after the expiry date printed on the packaging.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Strategic Advisory

Ms. Shiwani Dhiman

VP-Strategic Outreach & Engagement

Ms. Shiwani specializes in market outreach and strategic partnership orchestration for entrepreneurs building scalable PCD Pharma Franchise models.

View Professional Profile

Start Your Journey

Partner With Cafoli

Ready to Dominate your territory with a Monopoly-Based PCD Franchise? Join our rapidly growing network of successful franchise partners and turn your ambitions into reality. Limited Territories Available — Don’t Miss Out!

Quick Navigation